Ann: Resonance Contracted by Major Global Pharma, page-9

Positive news but this is a different business model being a CRO and comes with significant risks IMO. Well managed those risks are reduced and as always if trial is stopped there won't be te full fees.
This is being a CRO
Will be interesting to see what costs RHT will incur to achieve this income?

Not sure what the market will actually understand about how many $ fall to bottom line but it does give turnover an dmake fuller use of facilities and skills.

ASIC / ASX may ask for more details on this announcement

All intellectual property in the Study vests in the Customer.